American Century Companies Inc. Takes $48.17 Million Position in Bioverativ Inc (BIVV)
American Century Companies Inc. bought a new stake in shares of Bioverativ Inc (NASDAQ:BIVV) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 844,022 shares of the biotechnology company’s stock, valued at approximately $48,168,000. American Century Companies Inc. owned approximately 0.78% of Bioverativ at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. TCI Wealth Advisors Inc. bought a new position in Bioverativ during the third quarter valued at about $186,000. Canada Pension Plan Investment Board bought a new position in Bioverativ during the third quarter valued at about $194,000. Essex Investment Management Co. LLC bought a new position in Bioverativ during the third quarter valued at about $238,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in Bioverativ during the third quarter valued at about $242,000. Finally, Traynor Capital Management Inc. bought a new position in Bioverativ during the third quarter valued at about $244,000. Institutional investors own 95.16% of the company’s stock.
Bioverativ Inc (BIVV) opened at $53.66 on Monday. Bioverativ Inc has a 12 month low of $40.00 and a 12 month high of $64.41.
Bioverativ (NASDAQ:BIVV) last posted its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.25. The business had revenue of $291.60 million for the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The firm’s revenue was up 27.2% compared to the same quarter last year. sell-side analysts anticipate that Bioverativ Inc will post 2.45 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/11/13/american-century-companies-inc-takes-48-17-million-position-in-bioverativ-inc-bivv.html.
Several equities analysts have weighed in on BIVV shares. Zacks Investment Research upgraded Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 target price on the stock in a report on Tuesday, July 25th. Royal Bank Of Canada started coverage on Bioverativ in a report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 target price on the stock. Piper Jaffray Companies restated an “overweight” rating and set a $71.00 target price on shares of Bioverativ in a report on Monday, October 23rd. Evercore ISI started coverage on Bioverativ in a report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 target price on the stock. Finally, Morgan Stanley restated an “underweight” rating and set a $47.00 target price (up from $45.00) on shares of Bioverativ in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $61.73.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.